Cover Image
市場調查報告書

協和醱酵麒麟公司的產品平台分析

Kyowa Hakko Kirin Co., Ltd. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224561
出版日期 內容資訊 英文 125 Pages
訂單完成後即時交付
價格
Back to Top
協和醱酵麒麟公司的產品平台分析 Kyowa Hakko Kirin Co., Ltd. - Product Pipeline Review - 2016
出版日期: 2016年03月31日 內容資訊: 英文 125 Pages
簡介

協和醱酵麒麟公司是總公司設置在日本的生物科技企業,致力於製藥產品和生物科技產品的藥物研發、開發及商品化。開發的對象領域有腫瘤,腎臟疾病等。

本報告提供協和醱酵麒麟公司的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

協和醱酵麒麟公司的基本資料

  • 協和醱酵麒麟公司概要
  • 主要資訊
  • 企業資料

協和醱酵麒麟公司:R&D概要

  • 主要的治療範圍

協和醱酵麒麟公司:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

協和醱酵麒麟公司:開發中產品概況

  • 後期階段的開發中產品
    • 登記前階段的產品/聯合治療模式
    • 被登記拒絕/撤消做了的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

協和醱酵麒麟公司:藥物簡介

  • KW-3357
  • tivozanib
  • benralizumab
  • brodalumab
  • darbepoetin alfa (recombinant)
  • granisetron ER
  • istradefylline
  • mogamulizumab
  • tivantinib
  • ASKP-1240
  • bardoxolone methyl
  • KHK-4577
  • KRN-23
  • romiplostim
  • BIW-8962
  • KHK-2823
  • KHK-2898
  • KHK-4083
  • KHK-6640
  • DsiRNA to Inhibit KRAS for Solid Tumor
  • DsiRNAs for Solid Tumor
  • K-685
  • K-756
  • Ki-26894
  • KM-2812
  • KW-6356
  • Small Molecules to Inhibit Mitotic Kinesin Eg5 for Ovarian Cancer
  • Z-3G1
  • Bispecific Antibodies for Undisclosed Indication
  • K-777
  • Small Molecules Targeting Protein-Protein Interactions for Undisclosed Indication

協和醱酵麒麟公司:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

協和醱酵麒麟公司:最新的開發平台資訊

協和醱酵麒麟公司:開發暫停中的計劃

協和醱酵麒麟公司:開發中止的開發中產品

  • 開發中止的開發中產品簡介

協和醱酵麒麟公司:企業理念

協和醱酵麒麟公司:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08015CDB

Summary

Global Markets Direct's, 'Kyowa Hakko Kirin Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the Kyowa Hakko Kirin Co., Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kyowa Hakko Kirin Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Kyowa Hakko Kirin Co., Ltd.
  • The report provides overview of Kyowa Hakko Kirin Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Kyowa Hakko Kirin Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Kyowa Hakko Kirin Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Kyowa Hakko Kirin Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Kyowa Hakko Kirin Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Kyowa Hakko Kirin Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Kyowa Hakko Kirin Co., Ltd. Snapshot
    • Kyowa Hakko Kirin Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Kyowa Hakko Kirin Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Kyowa Hakko Kirin Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Kyowa Hakko Kirin Co., Ltd. - Pipeline Products Glance
    • Kyowa Hakko Kirin Co., Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Kyowa Hakko Kirin Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Kyowa Hakko Kirin Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Kyowa Hakko Kirin Co., Ltd. - Drug Profiles
    • brodalumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • darbepoetin alfa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • granisetron ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • romiplostim
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tivozanib hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • benralizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • burosumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • istradefylline
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mogamulizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MT-4580
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tivantinib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bardoxolone methyl
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bleselumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KHK-4083
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BIW-8962
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • antithrombin III (human)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • entinostat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KHK-2823
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KHK-2898
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KHK-6640
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CHKM-4927
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • K-685
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • K-756
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KHK-KRAS
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KHK-XXX
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KM-2812
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pr-1E11
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit ASK1 for Amyotropic Lateral Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Mitotic Kinesin Eg5 for Ovarian Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Z-3G1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • K-777
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules Targeting Protein-Protein Interactions for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Kyowa Hakko Kirin Co., Ltd. - Pipeline Analysis
    • Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Target
    • Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Route of Administration
    • Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Molecule Type
    • Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Mechanism of Action
  • Kyowa Hakko Kirin Co., Ltd. - Recent Pipeline Updates
  • Kyowa Hakko Kirin Co., Ltd. - Dormant Projects
  • Kyowa Hakko Kirin Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • AGS-004
      • darbepoetin alfa
      • KHK-2866
      • KHK-6188
      • KRN-330
      • KRX-0601
      • KW-2449
      • KW-2450
      • KW-2478
      • KW-7158
      • litronesib
      • mogamulizumab
      • pibrozelesin hydrobromide
      • rocapuldencel-t
      • SAR-252067
      • tivantinib
      • tivozanib hydrochloride
  • Kyowa Hakko Kirin Co., Ltd. - Company Statement
  • Kyowa Hakko Kirin Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Kyowa Hakko Kirin Co., Ltd., Key Information
  • Kyowa Hakko Kirin Co., Ltd., Key Facts
  • Kyowa Hakko Kirin Co., Ltd. - Pipeline by Indication, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Pipeline by Stage of Development, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Partnered Products in Pipeline, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Out-Licensed Products in Pipeline, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Pre-Registration, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Phase III, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Phase II, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Phase I, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Preclinical, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Discovery, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Pipeline by Target, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Pipeline by Route of Administration, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Pipeline by Molecule Type, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Recent Pipeline Updates, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Dormant Developmental Projects,2016
  • Kyowa Hakko Kirin Co., Ltd. - Discontinued Pipeline Products, 2016
  • Kyowa Hakko Kirin Co., Ltd., Other Locations
  • Kyowa Hakko Kirin Co., Ltd., Subsidiaries

List of Figures

  • Kyowa Hakko Kirin Co., Ltd. - Pipeline by Top 10 Indication, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Pipeline by Stage of Development, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Partnered Products in Pipeline, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Pipeline by Top 10 Target, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Pipeline by Route of Administration, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Pipeline by Molecule Type, 2016
  • Kyowa Hakko Kirin Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top